olivLaw · US equity research
X4 Pharmaceuticals, Inc. XFOR
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing therapies for rare hematology diseases, with mavorixafor as its main asset. The company now focuses its resources on the pivotal Phase 3 4WARD trial in chronic neutropenia, while its approved product XOLREMDI still generates modest revenue, at 35.1 million USD in 2025.
At the close of 02 Nov 2026, X4 Pharmaceuticals, Inc. (XFOR) stock was 3.35 USD (+0.00% on the day), with market capitalisation 332.1 m USD, beta 1.50, 52-week range 2.45–4.67 USD. Latest reported quarter (Q2 2026): revenue of 2.4 m USD (+41.2% YoY), net income of -16.2 m USD, diluted EPS -0.13 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 60.3
- strong (55–70)
- Bollinger (20, 2)
- 2.39 – 3.56
- in the upper half of the band · %B 0.82 · band width 39.2%
- SMA 50 / 200
- 3.31 / 3.80
- mixed trend
- MACD (12, 26, 9)
- 0.05 / -0.04
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +18.4% | −2.3% | +20.7 pp | — |
| 3 months | −18.1% | −0.8% | −17.3 pp | — |
| 6 months | −20.4% | +4.7% | −25.2 pp | — |
| Year to date | −16.2% | +10.2% | −26.4 pp | — |
| 1 year | −17.1% | +10.3% | −27.3 pp | −17.3% |
| 3 years | −88.2% | +73.0% | −161.2 pp | −25.1% |
| 5 years | −98.0% | +61.8% | −159.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 560.0 k | 1.5 m | 900.0 k | 1.7 m | 1.6 m | 2.2 m | 2.5 m | 2.4 m |
| Cost of revenue | 227.0 k | 302.0 k | 4.7 m | 326.0 k | 351.0 k | 364.0 k | 598.0 k | 1.6 m |
| Research & development | 19.2 m | 21.7 m | 18.5 m | 18.4 m | 17.3 m | 18.5 m | 15.5 m | 15.1 m |
| Operating income | -34.5 m | -35.7 m | -9.4 m | -26.2 m | -27.5 m | -23.7 m | -20.3 m | -16.4 m |
| Depreciation & amortisation | 267.0 k ≈ | 273.0 k | 476.0 k | 355.0 k ≈ | 223.0 k ≈ | 223.0 k | 223.0 k | 997.0 k ≈ |
| Interest expense | 2.4 m | 2.3 m | 2.2 m | 2.2 m | 2.3 m | 2.2 m | 2.1 m | 2.2 m |
| Pre-tax income | -36.7 m | -39.6 m | 316.0 k | -25.7 m | -29.8 m | -23.9 m | -20.2 m | -16.2 m |
| Income tax | 15.0 k | 258.0 k | 34.0 k | 37.0 k | -30.0 k | 0 | 0 | 2.0 k |
| Net income | -36.7 m | -39.8 m | 282.0 k | -25.7 m | -29.8 m | -23.9 m | -20.2 m | -16.2 m |
| Diluted EPS | -5.48 | -5.90 ≈ | 0.04 | -3.47 | -0.69 | -0.22 ≈ | -0.16 | -0.13 |
| Operating cash flow | -34.0 m ≈ | -33.0 m | -12.4 m | -29.9 m ≈ | -27.8 m ≈ | -15.5 m | -19.6 m | -20.8 m ≈ |
| Capex | 92.0 k ≈ | 41.0 k | 0 | 0 ≈ | 0 ≈ | 0 | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3.0 m | 0 | 0 | 0 | 2.6 m | 6.5 m |
| Revenue YoY | unavailable | unavailable | unavailable | −100.0% | unavailable | unavailable | unavailable | +150.0% |
| Net income | -33.3 m | -52.8 m | -62.1 m | -88.7 m | -93.9 m | -101.2 m | -37.5 m | -79.2 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -3.09 | -3.99 | -1.52 | -17.07 | -5.59 | -1.87 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | -2,071.0% | unavailable | unavailable | unavailable | -1,440.4% | -1,218.4% |
| Free cash flow | -25.4 m | -48.2 m | -60.2 m | -71.5 m | -77.2 m | -96.6 m | -131.2 m | -85.6 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 217.0 m USD
- Financial debt
- 75.0 m USD
- Net debt
- -142.0 m USD
- Equity
- 186.3 m USD
- Total assets
- 290.5 m USD
- Debt / equity
- 0.40x
- Current ratio
- 10.16x
- ROE
- -76.0%
- ROA
- -36.3%
- FCF margin
- -1,317.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 3.0 m | 0 | 0 | 0 | 2.6 m | 6.5 m | SEC (XBRL)· 17 Mar 2026verified |
| Cost of revenue | — | — | 0 | 0 | 797.0 k | 5.8 m | SEC (XBRL)· 17 Mar 2026verified |
| Gross profit | — | — | 0 ≈ | 0 ≈ | 1.8 m ≈ | 743.0 k ≈ | SEC (XBRL)· 17 Mar 2026derived |
| Research & development | 41.9 m | 50.6 m | 61.1 m | 72.0 m | 81.6 m | 72.7 m | SEC (XBRL)· 17 Mar 2026verified |
| Operating income | -59.9 m | -85.1 m | -87.6 m | -107.5 m | -36.4 m | -86.9 m | SEC (XBRL)· 17 Mar 2026verified |
| Depreciation & amortisation | 351.0 k | 499.0 k | 513.0 k | 419.0 k | 796.0 k | 1.3 m | SEC (XBRL)· 17 Mar 2026verified |
| EBITDA | -59.5 m ≈ | -84.6 m ≈ | -87.1 m ≈ | -107.1 m ≈ | -35.6 m ≈ | -85.6 m ≈ | SEC (XBRL)· 17 Mar 2026derived |
| Interest expense | 2.7 m | 3.6 m | 4.0 m | 5.8 m | 8.8 m | 8.9 m | SEC (XBRL)· 17 Mar 2026verified |
| Pre-tax income | -62.0 m | -88.7 m | -93.8 m | -101.1 m | -37.1 m | -79.2 m | SEC (XBRL)· 17 Mar 2026verified |
| Income tax | 148.0 k | 17.0 k | 28.0 k | 78.0 k | 310.0 k | 41.0 k | SEC (XBRL)· 17 Mar 2026verified |
| Net income | -62.1 m | -88.7 m | -93.9 m | -101.2 m | -37.5 m | -79.2 m | SEC (XBRL)· 17 Mar 2026verified |
| Diluted EPS | -3.09 | -3.99 | -1.52 | -17.07 | -5.59 | -1.87 | SEC (XBRL)· 17 Mar 2026verified |
| Weighted average diluted shares | 20.1 m | 25.7 m | 63.5 m | 5.9 m | 6.7 m | 42.3 m | SEC (XBRL)· 17 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 78.7 m | 81.8 m | 121.7 m | 99.2 m | 55.7 m | 217.0 m | SEC (XBRL)· 17 Mar 2026verified |
| Receivables | — | — | — | 0 | 1.1 m | 573.0 k | SEC (XBRL)· 17 Mar 2026verified |
| Inventories | — | — | — | 0 | 2.8 m | — | SEC (XBRL)· 26 Mar 2025verified |
| Current assets | 83.3 m | 87.9 m | 128.7 m | 122.1 m | 112.2 m | 261.6 m | SEC (XBRL)· 17 Mar 2026verified |
| Property, plant & equipment, net | 1.2 m | 1.5 m | 1.1 m | 745.0 k | 776.0 k | 182.0 k | SEC (XBRL)· 17 Mar 2026verified |
| Goodwill | 27.1 m | 17.4 m | 17.4 m | 17.4 m | 17.4 m | 17.4 m | SEC (XBRL)· 17 Mar 2026verified |
| Intangibles (excl. goodwill) | — | — | — | 0 | 10.0 m | 9.3 m | SEC (XBRL)· 17 Mar 2026verified |
| Total assets | 122.9 m | 117.2 m | 155.6 m | 147.3 m | 146.4 m | 290.5 m | SEC (XBRL)· 17 Mar 2026verified |
| Accounts payable | 3.1 m | 4.3 m | 7.8 m | 8.9 m | 8.6 m | 5.7 m | SEC (XBRL)· 17 Mar 2026verified |
| Short-term debt | 0 | 795.0 k | 1.3 m | 0 | — | — | SEC (XBRL)· 21 Mar 2024verified |
| Long-term debt | 33.2 m | 33.1 m | 32.3 m | 54.6 m | 75.0 m | 75.0 m | SEC (XBRL)· 17 Mar 2026verified |
| Current liabilities | 11.9 m | 14.0 m | 22.3 m | 22.9 m | 32.9 m | 25.8 m | SEC (XBRL)· 17 Mar 2026verified |
| Total liabilities | 50.1 m | 52.8 m | 81.5 m | 96.2 m | 124.3 m | 104.2 m | SEC (XBRL)· 17 Mar 2026verified |
| Equity | 72.8 m † | 64.4 m † | 74.1 m † | 51.1 m † | 22.1 m † | 186.3 m † | SEC (XBRL)· 17 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -58.8 m | -70.9 m | -77.1 m | -96.5 m | -130.9 m | -85.6 m | SEC (XBRL)· 17 Mar 2026verified |
| Capex | 1.4 m | 615.0 k | 103.0 k | 60.0 k | 326.0 k | 0 | SEC (XBRL)· 17 Mar 2026verified |
| Free cash flow | -60.2 m ≈ | -71.5 m ≈ | -77.2 m ≈ | -96.6 m ≈ | -131.2 m ≈ | -85.6 m ≈ | SEC (XBRL)· 17 Mar 2026derived |
| Investing cash flow | -1.4 m | -615.0 k | -103.0 k | -14.9 m | 67.0 m | 8.2 m | SEC (XBRL)· 17 Mar 2026verified |
| Financing cash flow | 12.4 m | 74.2 m | 117.2 m | 88.5 m | 20.3 m | 238.6 m | SEC (XBRL)· 17 Mar 2026verified |
| Share repurchases | 0 | 2.0 m | 0 | 0 | — | — | SEC (XBRL)· 21 Mar 2024verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 35.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
02 Nov 2026Source: olivLaw, closing series
Market cap: 332.1 m USD
Key indicators
Coverage and freshness
Score by group
35% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -196.6% | 10 (vs peers) | 29% |
| Net margin · Quality | -1,040.1% | 33 (vs peers) | 18% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -10.1x | 0 (on a fixed band) | 18% |
| Current ratio · Balance sheet | 11.3x | 100 (on a fixed band) | 12% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -25.2% | 0 (on a fixed band) | 24% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality19/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
X4 PHARMACEUTICALS, INC (XFOR). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 6.5 m USD in 2025; YoY growth 150.0%; net margin -1,040.1%; ROE -113.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 35.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 11.3x
What contradicts it
- ROIC: -196.6%
- Interest coverage: -10.1x
- FCF yield: -25.2%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 251.6 bn | 28.9 | 91.5% | 23.0% | +10.0% | +35% / +73% |
| GILDGilead Sciences, Inc. | 211.3 bn | — | -22.3% | -12.5% | +2.4% | +35% / +122% |
| MRNAModerna, Inc. | 88.2 bn | — | -39.0% | -141.4% | −39.9% | +750% / +184% |
| RVMDRevolution Medicines, Inc. | 40.3 bn | — | -79.1% | — | unavailable | +142% / +707% |
| BIIBBiogen Inc. | 36.8 bn | 106.4 | 1.9% | 3.4% | +2.2% | +37% / +6% |
| EXELExelixis, Inc. | 17.1 bn | 21.0 | 44.3% | 35.5% | +7.0% | +59% / +222% |
| NBIXNeurocrine Biosciences, Inc. | 14.7 bn | 21.6 | 20.4% | 19.0% | +21.4% | −4% / +25% |
| RGENRepligen Corp | 11.1 bn | — | -0.6% | -1.5% | +16.4% | +1% / +10% |
| QGENQiagen N.V. | 10.9 bn | 26.0 | 11.6% | 20.3% | +5.7% | +5% / +19% |
| CRSPCrispr Therapeutics AG | 4.8 bn | — | -25.6% | -1,812.1% | −90.6% | −7% / −25% |
| IOVAIovance Biotherapeutics, Inc. | 3.6 bn | — | -40.4% | -89.1% | +60.6% | +225% / +32% |
| BEAMBeam Therapeutics Inc. | 2.7 bn | — | -8.1% | -54.7% | +120.0% | +2% / −8% |
| RXRXRecursion Pharmaceuticals, Inc. | 2.4 bn | — | -48.7% | -697.1% | +26.9% | −17% / −44% |
| MAZEMaze Therapeutics, Inc. | 1.7 bn | — | -37.3% | -5,343.6% | unavailable | −20% / unavailable |
| NVAXNovavax Inc | 1.6 bn | — | — | -59.9% | +64.7% | +35% / +73% |
| ALVOAlvotech | 1.4 bn | 44.8 | — | 4.8% | +19.7% | −12% / −53% |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −51% / −93% |
| DNAGinkgo Bioworks Holdings, Inc. | 627.6 m | — | -56.3% | -260.0% | −25.1% | +6% / −81% |
| RGNXREGENXBIO Inc. | 472.7 m | — | -137.6% | -112.6% | +104.5% | −47% / −63% |
| FENCFennec Pharmaceuticals Inc. | 369.6 m | — | -18.6% | -5.5% | −6.1% | +29% / +23% |
| SRZNSurrozen, Inc. | 341.1 m | — | — | -2,885.3% | −67.4% | +75% / +303% |
| XFORX4 Pharmaceuticals, Inc | 332.1 m | — | -113.1% | -1,040.1% | +150.0% | −17% / −88% |
| ALGSAligos Therapeutics, Inc. | 196.0 m | — | -113.6% | -2,031.1% | −39.5% | −52% / −74% |
| CGENCompugen Ltd | 187.2 m | 5.2 | 44.8% | 48.6% | +161.1% | +27% / +200% |
| IVVDInvivyd, Inc. | 171.5 m | — | -95.9% | -183.9% | +110.5% | −76% / −62% |
1- and 3-year price returns: for XFOR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing therapies for rare hematology diseases, with mavorixafor as its main asset. The company now focuses its resources on the pivotal Phase 3 4WARD trial in chronic neutropenia, while its approved product XOLREMDI still generates modest revenue, at 35.1 million USD in 2025 1.
SWOT
Strengths
- The company has a product approved in the US and under authorization in the EU, which reduces technical risk compared with a wholly new asset 12.
- Mavorixafor holds favorable regulatory designations, including Fast Track for chronic neutropenia, which could accelerate approval 1.
- Access to capital in 2025 strengthened the balance sheet and extended the funding horizon, giving time to complete the study 13.
Weaknesses
- The company has recurring losses and product revenue remains low, making dependence on external financing very high 1.
- Strategy depends almost entirely on one asset, and the 2025 restructurings significantly reduced operating capacity 1.
- Production relies on single third-party suppliers, creating supply chain vulnerabilities 1.
Opportunities
- If the 4WARD study supports the chronic neutropenia indication, the potential market could be much larger than the current product market 13.
- Additional partnerships in other regions could bring licensing revenue without large direct commercial costs 1.
- Oral administration could attract patients who reject injectable treatments and could reduce G-CSF doses 1.
Risks
- Need for additional fundinghigh
Operations require continued funding until profitability, and limited access to capital could force the company to reduce or delay development programs 1.
- Results of the 4WARD studyhigh
If the pivotal study does not meet its primary criteria, the commercial outlook for mavorixafor in neutropenia could be seriously affected 1.
- Enrollment delays and design changesmedium
Discussions with the FDA on sample size and the transfer of trial management to a CRO could delay the study timetable 2.
- Dependence on a single producthigh
Almost the entire strategy depends on mavorixafor, so any technical or regulatory problem would have a major effect on the company 1.
- Dependence on third-party suppliersmedium
Manufacture of the active ingredient and capsules relies on single suppliers, and their problems could delay production 1.
Investment thesis
What would need to be true (bull case)
- If the 4WARD study confirms efficacy in chronic neutropenia, the company could capture a market far larger than today's 13.
- EU authorization and the Norgine partnership could generate additional revenue and ease financial pressure 2.
- Favorable regulatory designations could accelerate the approval timeline if clinical data are solid 1.
What would break the thesis
- Continued net losses and low revenue could force the company into further share issuances, diluting existing shareholders 1.
- A failure of the pivotal study could leave the company without a second major product and could sharply reduce its value 1.
- Timeline delays could extend the period of cash burn and increase funding pressure 2.
What to watch
- Outcome of FDA discussions on the 4WARD sample size and completion of enrollmentQ3 2026
- European Commission decision and XOLREMDI sales trend after the transfer to Norgine2026
- Top-line results from the 4WARD trial2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
During 2025 the company carried out successive restructurings that reduced headcount by approximately 65% and changed its executive leadership 1. Revenue rose to 35.1 million USD in 2025, supported mainly by the Norgine license, while the net loss remained significant 1. Liquidity, supported by two capital transactions, could fund operations into 2028, subject to compliance with the Hercules loan covenants 13.
Segments
Mavorixafor in chronic neutropenia
This is the company's main focus, with the 4WARD study as the decisive step. The targeted population includes patients with serious or recurring infections, estimated at about 15000 in the US 13. If the study supports the indication, a launch could open a commercial segment much larger than the WHIM market 3.
XOLREMDI for WHIM syndrome
The product approved in the US and authorized in the EU generates limited revenue, with net product sales of 6.5 million USD in 2025 1. The company reduced investment in this indication to focus resources on chronic neutropenia while keeping patient access 12. EU authorization was granted in April 2026 and the file was transferred to Norgine in July 2026 2.
Market context
Trends
- Focus on rare disease medicinetailwind
Regulators grant accelerated designations for rare diseases, which can shorten the path to approval for mavorixafor, as seen with Fast Track designation for chronic neutropenia 1. This context could support the product if data from 4WARD prove favorable 1.
- Strict requirements for pivotal studiesheadwind
Sample size adjustments and re-enrollment can extend study timelines, and the company has announced discussions with the FDA on this topic 2. Delays could postpone launch and increase the need for funding 2.
- Pricing and reimbursement pressureheadwind
Legislation and negotiations with payors can influence the price obtained and access to treatment, a factor the company explicitly flags as a risk 1. The effect on future revenue could be significant depending on the rules adopted 1.
- Partnerships with pharmaceutical companiesmixed
Regional licensing, such as the agreements with Norgine and with partners in the Middle East and China, can bring revenue and reduce commercial risk 1. Over the longer term such collaborations could help fund development 1.
Competitive position
Direct competition comes from existing injectable neutropenia therapies, especially G-CSF, which is the current standard of care 1. The company describes the pharmaceutical industry as highly competitive and subject to rapid technological change that could make products less attractive 1.
The company's advantage lies in oral administration, an alternative that could reduce dependence on injections and repeated dosing 1. Other developers of CXCR4-targeted therapies or other neutropenia products could reach the market in parallel, which could reduce future market share 1.
- G-CSF (injectable reference therapy)
The current treatment for chronic neutropenia, given by injection, with adverse effects that limit long-term use.
- Other CXCR4-targeting developers
Companies exploring modulation of the CXCR4/CXCL12 axis for hematologic and oncologic conditions, potential competitors over the medium term.
- Regional distribution partners
Partners that commercialize the product in certain regions; they are not direct competitors but influence access and revenue.
- Oral therapies in development for neutropenia
Products in research that could compete in the oral segment if they reach the market.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report29 Oct 2026Other events · Financial statements and exhibits
- Current report08 Oct 2026Material agreement · Termination of a material agreement · Creation of a direct financial obligation · Item 3.02 · Regulation FD disclosure · Financial statements and exhibits
- Current report09 Sept 2026Other events · Financial statements and exhibits
- Current report08 Sept 2026Other events · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report01 Jul 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report (amendment)13 May 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Current report12 May 2026Departure or appointment of officers · Shareholder vote
- Quarterly report06 May 2026
- Proxy statement20 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / X4 Pharmaceuticals, Inc. · 17 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / X4 Pharmaceuticals, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / X4 Pharmaceuticals, Inc. · 05 Nov 2025
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.